Prescription analysis of dipeptidyl peptidase-4 inhibitors for outpatients with type 2 diabetes in Hiroshima
-
- Sako Yuki
- K.D.Fudo Co.,LTD
-
- Mikami Ikue
- Yasuda Women’s university
-
- Kiribayashi Yoshie
- K.D.Fudo Co.,LTD
-
- Shigeyama Masato
- Yokohama University of Pharmacy
-
- Yamaguchi Tomoaki
- Yokohama University of Pharmacy
Bibliographic Information
- Other Title
-
- 広島県における2型糖尿病治療でのDPP-4阻害剤の処方動向調査
Search this article
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors may overcome various problems in the treatment of type 2 diabetes. However, the combination therapy-related onset of severe hypoglycemia must be considered. We conducted a prescription trend survey of DPP-4 inhibitors to clarify the current status. The survey period was from January 2010 until December 2012. The subjects were 1,172 patients for whom DPP-4 inhibitors were prescribed at Life Art Group pharmacies (Hiroshima Prefecture), with a mean age of 68±12 years. As DPP-4 inhibitors, sitagliptin was administered to 687 patients, alogliptin to 390, vildagliptin to 94, and linagliptin to 1. Furthermore, monotherapy with a DPP-4 inhibitor was performed in 324 patients, combination therapy with a sulfonylurea (SU) preparation in 195, combination therapy with a biguanide (BG) preparation in 135, and combination therapy with SU and BG preparations in 118. Of SU preparations combined with DPP-4 inhibitors, glimepiride accounted for 74% of 262 patients, and prescriptions at 2 mg/day or less accounted for 87%. DPP-4 inhibitors are used for both monotherapy and combination therapy for type 2 diabetes. The principle of starting administration at a low dose when combining DPP-4 inhibitors with SU preparations must be obeyed.
Journal
-
- Diabetes Frontier Online
-
Diabetes Frontier Online 2 (e1), 013-013, 2015-12-22
Medical Review Co.,Ltd
- Tweet
Details 詳細情報について
-
- CRID
- 1390002212173517952
-
- ISSN
- 21887527
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
-
- Abstract License Flag
- Disallowed